Viking Therapeutics Inc

Latest Results (20.11.2025):

Viking Therapeutics Inc — Q3 2025: In its report for the quarter and nine months ended September 30, 2025, Viking highlighted material clinical progress while reporting a strong quarter-end cash balance of $715 million. The company emphasized Phase 3 VANQUISH enrollment progressing on schedule, positive Phase 2 VENTURE-Oral top-line results, and ongoing development of both oral and subcutaneous VK2735 formulations; the report does not disclose conventional GAAP metrics such as revenue, net income or EPS.

Cash position

Quarter-end cash and equivalents were reported at $715 million, which the company states is sufficient to fund VK2735 through the VANQUISH Phase 3 program and support other pipeline activities.

VENTURE-Oral top-line results

Phase 2 VENTURE-Oral achieved its primary and secondary endpoints: up to 12.2% mean weight loss after 13 weeks, dose-dependent and progressive reductions, high proportions achieving ≥5% and ≥10% weight loss (up to 97% and 80% respectively), and largely mild-to-moderate treatment-emergent adverse events. An exploratory maintenance cohort showed durable weight loss after down-titration.

VANQUISH Phase 3 progress

Phase 3 VANQUISH program for subcutaneous VK2735 is underway with two trials (VANQUISH‑1 ~4,500 subjects; VANQUISH‑2 ~1,100 subjects) randomized to 7.5 mg, 12.5 mg, 17.5 mg or placebo for 78 weeks. Enrollment is proceeding well; VANQUISH‑1 enrollment expected complete by end of 2025 and VANQUISH‑2 in Q1 2026.

Prior subcutaneous data and formulation strategy

Earlier Phase 2 VENTURE subcutaneous data showed up to 14.7% mean weight loss after 13 weekly doses with encouraging tolerability. Viking’s strategy includes both subcutaneous and oral formulations using the same molecule to offer initiation and maintenance options and potentially ease transitions between dosing modalities.

Near-term catalysts

Near-term events include completion of VANQUISH‑1 enrollment (end of 2025), VANQUISH‑2 enrollment (1Q 2026), additional Phase 2a VENTURE data to be presented at ObesityWeek in November, an IND filing for an amylin agonist program planned in 1Q 2026, and a conference call scheduled for 4:30 p.m. ET today.

Absent financial detail

Aside from the $715 million cash balance, the company’s report does not disclose standard earnings details (revenues, net loss/profit, EPS, or formal guidance), so investors must rely primarily on liquidity and clinical development updates provided here.